Literature DB >> 16369743

Comparison of three radiotherapy treatment planning protocols of definitive external-beam radiation for localized prostate cancer.

SuYu Zhu1, Takashi Mizowaki, Yasushi Nagata, Kenji Takayama, Yoshiki Norihisa, Shinsuke Yano, Masahiro Hiraoka.   

Abstract

BACKGROUND: Three radiotherapy treatment planning (RTTP) protocols for definitive external-beam radiation for localized prostate cancer, designed and clinically applied at Kyoto University, were compared.
METHODS: Treatment plans were created according to three different RTTP protocols (old three-dimensional conformal radiotherapy [3D-CRT], new 3D-CRT, and intensity-modulated radiotherapy [IMRT]) on computed tomography (CT) data sets of five patients with localized prostate cancer. The dynamic-arc conformal technique was used in the 3D-CRT protocols. Differences in dose distribution were evaluated and compared based on dose-volume histogram (DVH) analyses.
RESULTS: The coverage of the clinical target volume (= prostate alone) was comparable among the three RTTP protocols. However, the average values for the percent volume that received at least 95% of the prescription dose (V95), the percent of the prescription dose covering 95% of the volume (D95), and the conformity index of the planning target volume (PTV) were 99%, 97%, and 0.88 for the IMRT; 93.9%, 94.5%, and 0.76 for the new 3D-CRT; and 59.6%, 82.9%, and 0.6 for the old 3D-CRT protocol, respectively. Inhomogeneity of doses to the PTV was larger with the IMRT protocol than with the new 3D-CRT protocol. Doses to both the rectal wall and bladder wall were almost comparable with the new 3D-CRT and IMRT protocols, but were lower with the old 3D-CRT protocol, due to the lowest prescription dose and incomplete dose coverage of the PTV.
CONCLUSION: The old 3D-CRT protocol could not achieve the goals for the PTV set in the IMRT protocol. The new 3D-CRT and IMRT protocols were generally comparable in terms of both the PTV coverage and normal tissue-sparing, although the IMRT protocol achieved the most conformal dose distribution to the PTV, in return for a larger, but acceptable, dose inhomogeneity.

Entities:  

Mesh:

Year:  2005        PMID: 16369743     DOI: 10.1007/s10147-005-0519-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.850


  19 in total

1.  A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate.

Authors:  A van't Riet; A C Mak; M A Moerland; L H Elders; W van der Zee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-02-01       Impact factor: 7.038

2.  Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.

Authors:  M J Zelefsky; D Cowen; Z Fuks; M Shike; C Burman; A Jackson; E S Venkatramen; S A Leibel
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

3.  X-ray field compensation with multileaf collimators.

Authors:  T R Bortfeld; D L Kahler; T J Waldron; A L Boyer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-02-01       Impact factor: 7.038

4.  Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?

Authors:  D Keyser; P A Kupelian; C D Zippe; H S Levin; E A Klein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-01       Impact factor: 7.038

5.  External beam radiotherapy dose response of prostate cancer.

Authors:  A Pollack; G K Zagars
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-12-01       Impact factor: 7.038

6.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.

Authors:  M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel
Journal:  Radiother Oncol       Date:  2000-06       Impact factor: 6.280

7.  Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study.

Authors:  G E Hanks; T E Schultheiss; A L Hanlon; M Hunt; W R Lee; B E Epstein; L R Coia
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-02-01       Impact factor: 7.038

8.  Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate.

Authors:  C Burman; C S Chui; G Kutcher; S Leibel; M Zelefsky; T LoSasso; S Spirou; Q Wu; J Yang; J Stein; R Mohan; Z Fuks; C C Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-11-01       Impact factor: 7.038

9.  Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center.

Authors:  J E Fowler; N T Braswell; P Pandey; L Seaver
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

10.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

Authors:  M J Zelefsky; S A Leibel; P B Gaudin; G J Kutcher; N E Fleshner; E S Venkatramen; V E Reuter; W R Fair; C C Ling; Z Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-06-01       Impact factor: 7.038

View more
  12 in total

1.  Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer.

Authors:  Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Itaru Ikeda; Haruo Inokuchi; Kiyonao Nakamura; Tomomi Kamba; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2016-02-03       Impact factor: 3.402

2.  Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.

Authors:  Alexei Trofimov; Paul L Nguyen; John J Coen; Karen P Doppke; Robert J Schneider; Judith A Adams; Thomas R Bortfeld; Anthony L Zietman; Thomas F Delaney; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-21       Impact factor: 7.038

3.  Comparisons of the impact of systematic uncertainties in patient setup and prostate motion on doses to the target among different plans for definitive external-beam radiotherapy for prostate cancer.

Authors:  Su Yu Zhu; Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Yasushi Nagata; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2008-02-29       Impact factor: 3.402

4.  Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.

Authors:  Michihide Mitsumori; Yoshihide Sasaki; Takashi Mizowaki; Kenji Takayama; Yasushi Nagata; Masahiro Hiraoka; Yoshiharu Negoro; Keisuke Sasai; Hidefumi Kinoshita; Toshiyuki Kamoto; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2006-10       Impact factor: 3.402

5.  Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer.

Authors:  Takashi Mizowaki; Kenji Takayama; Yoshiki Norihisa; Masakazu Ogura; Tomomi Kamba; Takahiro Inoue; Yosuke Shimizu; Toshiyuki Kamoto; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2011-10-05       Impact factor: 3.402

6.  Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol.

Authors:  Yoshiki Norihisa; Takashi Mizowaki; Kenji Takayama; Yuki Miyabe; Kiyotomo Matsugi; Yukinori Matsuo; Masaru Narabayashi; Katsuyuki Sakanaka; Akira Nakamura; Yasushi Nagata; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2011-09-29       Impact factor: 3.402

7.  Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer.

Authors:  Masato Sakamoto; Takashi Mizowaki; Michihide Mitsumori; Kenji Takayama; Keisuke Sasai; Yoshiki Norihisa; Toshiyuki Kamoto; Eijiro Nakamura; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2010-07-23       Impact factor: 3.402

8.  Dosimetric evaluation of intensity modulated radiotherapy and 4-field 3-d conformal radiotherapy in prostate cancer treatment.

Authors:  Bora Uysal; Murat Beyzadeoğlu; Omer Sager; Ferrat Dinçoğlan; Selçuk Demiral; Hakan Gamsız; Serdar Sürenkök; Kaan Oysul
Journal:  Balkan Med J       Date:  2013-03-01       Impact factor: 2.021

9.  Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.

Authors:  Rihito Aizawa; Kenji Takayama; Kiyonao Nakamura; Takahiro Inoue; Toshinari Yamasaki; Takashi Kobayashi; Shusuke Akamatsu; Osamu Ogawa; Takashi Mizowaki
Journal:  Int J Clin Oncol       Date:  2019-12-09       Impact factor: 3.402

10.  Surveillance on interfacility differences in dose-prescription policy of intensity-modulated radiation therapy plans for prostate cancer.

Authors:  Takashi Mizowaki; Kazuo Hatano; Masahiro Hiraoka
Journal:  J Radiat Res       Date:  2012-06-06       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.